Literature DB >> 20426539

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.

E Borgen1, B Naume, J M Nesland, G Kvalheim, K Beiske, O Fodstad, I Diel, E F Solomayer, P Theocharous, R C Coombes, B M Smith, E Wunder, J P Marolleau, J Garcia, K Pantel.   

Abstract

BACKGROUND: Detection of isolated tumor cells (TC) in BM from carcinoma patients can predict future relapse. Various molecular and immunocytochemical (ICC) methods have been used to detect these cells, which are present at extremely low frequencies of 10(-5) - 10(-6). The specificity and sensitivity of these techniques may vary widely. In 1996, a European ISHAGE Working Group was founded to standardize and optimize procedures used for the detection of minimal residual disease. We have attempted to develop objective criteria for the evaluation of immunocytochemically identifiable cancer cells.
METHODS: An interlaboratory ring experiment was performed, to compare the screening and detection of micrometastasis-positive events between different laboratories. The discrepant results induced us to establish a common consensus on morphological criteria applicable to the identification of immunostained micrometastatic TC.
RESULTS: Bared on this consensus evaluation, we propose a classification of stained elements into three groups: (1) 'TC's show pathognomonic signs of epithelial TC-nature, as defined by a clearly enlarged nucleus or clusters of > or = 2 immunopositive cells. (2) 'Probable TC's represent morphological overlap between hematopoietic cells (HC) and TC which lack pathognomonic signs of TC-nature, but do not exhibit clear morphological features of HC. These cells are considered as TC if control staining with an isotype-specific, unrelated Ab is negative. (3) 'TC-negative' cells are defined as 'false positive' HC, skin squamous epithelial cells and artefacts. DISCUSSION: The proposed classification of immunostained events is a first step towards the development of standardized immunocytochemical assays for the detection of occult micrometastatic TC in BM or blood.

Entities:  

Mesh:

Year:  1999        PMID: 20426539     DOI: 10.1080/0032472031000141283

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  76 in total

1.  Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins.

Authors:  Sven Becker; Graziella Becker-Pergola; Tanja Fehm; Robert Emig; Diethelm Wallwiener; Erich-Franz Solomayer
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

2.  The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.

Authors:  Yogesh Kumar Vashist; Asad Kutup; Safije Musici; Emre F Yekebas; Sormeh Mina; Guentac Uzunoglu; Oliver Zehler; Alexandra Koenig; Guelle Cataldegirmen; Maximillian Bockhorn; Katharina Effenberger; Viacheslav Kalinin; Klaus Pantel; Jakob R Izbicki
Journal:  Cell Oncol (Dordr)       Date:  2011-02-22       Impact factor: 6.730

3.  Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.

Authors:  Antonia M S Müller; Holbrook E K Kohrt; Steven Cha; Ginna Laport; Jared Klein; Alice E Guardino; Laura J Johnston; Keith E Stockerl-Goldstein; Elie Hanania; Christopher Juttner; Karl G Blume; Robert S Negrin; Irving L Weissman; Judith A Shizuru
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

4.  The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.

Authors:  Nigel P Murray; Eduardo Reyes; Anibal Salazar; Marco Antonio Lopez; Shenda Orrego; Eghon Guzman
Journal:  Turk J Urol       Date:  2020-03-11

5.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

6.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.

Authors:  Tanja Fehm; Oliver Hoffmann; Bahriye Aktas; Sven Becker; Erich F Solomayer; Diethelm Wallwiener; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Cancer Res       Date:  2009-08-10       Impact factor: 6.466

7.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Authors:  Bjørn Naume; Xi Zhao; Marit Synnestvedt; Elin Borgen; Hege Giercksky Russnes; Ole Christian Lingjaerde; Maria Strømberg; Gro Wiedswang; Gunnar Kvalheim; Rolf Kåresen; Jahn M Nesland; Anne-Lise Børresen-Dale; Therese Sørlie
Journal:  Mol Oncol       Date:  2007-04-04       Impact factor: 6.603

Review 8.  Circulating tumor cells in breast cancer: methodology and clinical repercussions.

Authors:  J M Gasent Blesa; V Alberola Candel; E Esteban González; J Vidal Martínez; R Gisbert Criado; M Provencio Pulla; J Laforga Canales; K Pachmann
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

9.  Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study.

Authors:  Manuel Valladares-Ayerbes; Pilar Iglesias-Díaz; Silvia Díaz-Prado; Daniel Ayude; Vanessa Medina; Mar Haz; Margarita Reboredo; Silvia Antolín; Lourdes Calvo; Luis M Antón-Aparicio
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-17       Impact factor: 4.553

10.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.

Authors:  Tanja Fehm; Natalia Krawczyk; Erich-Franz Solomayer; Graziella Becker-Pergola; Silke Dürr-Störzer; Hans Neubauer; Harald Seeger; Annette Staebler; Diethelm Wallwiener; Sven Becker
Journal:  Breast Cancer Res       Date:  2008-09-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.